Skip to content
‹ Back to IndustriesHealthcare

Making Bright Ideas Work: The Trade Group Looking Out for the MedTech Community

Perhaps no state is more renowned for medicine than Massachusetts. The Commonwealth is host to leading hospitals, medical centers, and medical device companies that are maturing next generation technologies. But medtech enterprises large and small need representatives to ensure that innovations in the space can thrive. That’s where Brian Johnson comes in. He is…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI in a free MarketScale workspace. Qualifying companies also get one professional video edit a month. No credit card.

Start free

Perhaps no state is more renowned for medicine than Massachusetts. The Commonwealth is host to leading hospitals, medical centers, and medical device companies that are maturing next generation technologies. But medtech enterprises large and small need representatives to ensure that innovations in the space can thrive.

That’s where Brian Johnson comes in. He is President of the Massachusetts Medical Device Industry Council (MassMEDIC) and on this week’s episode of Making Bright Ideas Work, a Sunrise Labs podcast, he shared insights into his advocacy work.

“We help maintain a healthy environment for medical device innovators,” Johnson said. Medicine is a highly regulated industry so his trade group works with government partners to streamline processes and ensure a healthy ecosystem that fosters innovation.

Whether its pushing for the repeal of the medical device tax or staying atop of Brexit and its complications for medical device companies, MassMEDIC is there looking out for its members and the medtech community as a whole.

“Massachusetts continues to be a robust environment in this space,” he contended, and cited Sunrise Labs as one of the leaders pushing medtech forward. He also works with a number of startups disrupting the industry, and advises that novice CEOs should focus less energy on raising money and more on their plan to go from zero to commercialization.

“You need to think about the entire lifespan of this company as a founder,” Johnson said.

As a former company founder himself, Brian feels passionately about helping other founders. It’s why he’s become a personal champion of MassMEDIC IGNITE, which provides the medtech startup community with training, mentorship, and networking.

“I really love medtech,” Johnson confessed, and said that the innovations advanced by medical device companies are on par with those of the space program.

He is proud and amazed at the medical advances that come out of the Commonwealth. The first surgery with anesthesia was done in Massachusetts and now leading hospitals in the state are performing surgeries using advanced robotics or remote surgeons.

For the latest news, videos, and podcasts in the Healthcare Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @HealthMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0. No credit card. Company confirmation required.

More Healthcare Insights

Medicare will pay up to $137.53 per case in 2027 for BriefCase‑Triage

Medicare will pay up to $137.53 per case in 2027 for BriefCase‑Triage

Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage. Holland & Knight said hospitals will be eligible for NTAP reimbursement for use of Aidoc’s CARE Body CT Multi-Triage beginning Oct. 1, 2026, with supplemental payments continuing for three years.

  • 01Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage.
  • 02Holland & Knight said CMS approved an NTAP designation for Aidoc’s CARE Body CT Multi-Triage, with hospitals eligible for NTAP reimbursement beginning Oct. 1, 2026, with supplemental payments continuing for three years.

Sep 23, 2026

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raised CAD $4.24 million in a pre-seed round, according to Fierce Healthcare. It plans to expand protocol-driven virtual specialty care across Canada and the U.S.

  • 01Blair Health raised CAD $4.24 million in pre-seed funding.
  • 02Qualified Health positions its AI platform around safety and governance, including clinician oversight, auditability and traceability, according to Fierce Healthcare.

Sep 23, 2026

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512